Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
electroCore, Inc. filings document the regulatory record of a commercial-stage bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation products. Current reports include financial results, guidance, preliminary estimates, and business updates tied to prescription sales, VA channel activity, direct-to-consumer Truvaga sales, and Quell product revenue.
The filings also cover capital-structure and governance matters, including common stock issuances, resale registration obligations, board composition, executive changes, and related material-event disclosures. These records describe electroCore’s operating performance, product commercialization, financing activity, and public-company governance framework.
Hilve Holdings Limited and Mikhail Stiskin disclosed beneficial ownership of 432,000 shares of electroCore, Inc. common stock, representing 5.7% of the outstanding shares based on 7,583,445 shares outstanding as of August 5, 2025. Hilve Holdings, a Cyprus company, holds the shares directly and has sole voting and dispositive power over them. Mr. Stiskin, an Israeli citizen and sole shareholder of Hilve Holdings, may be deemed the beneficial owner with identical sole voting and dispositive power. The filing states the stake was not acquired to change or influence control of the issuer.
electroCore, Inc. director Patricia Wilber received an annual award of 19,011 restricted stock units (RSUs) on 09/02/2025 that vest in 12 equal monthly installments from the grant date, but will vest in full earlier if the company holds its next annual meeting or upon a change of control, provided she remains in continuous service.
Following this grant, Ms. Wilber beneficially owns 72,325 shares, which includes 16,583 shares that vested from prior RSU grants and were previously reported. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.
Julie Ann Goldstein, a director of electroCore, Inc. (ECOR), reported an award of 19,011 Annual Deferred Stock Units on 09/02/2025. The units were issued at a $0.00 price and vest in 12 equal monthly installments from the grant date; they vest in full earlier if the reporting person remains in service until the close of business one business day prior to the issuer's next annual stockholder meeting or immediately prior to a change of control. Following the grant, the filing reports 101,387 shares beneficially owned, which includes 10,000 previously vested shares and 1,665 shares held in NeuroSpine Ventures for which the reporting person disclaims beneficial ownership except for pecuniary interest. The Form 4 was signed by attorney-in-fact John L. Cleary, II on 09/04/2025.
electroCore, Inc. director Thomas J. Errico reported an award of 26,615 annual deferred stock units (DSUs) granted on 09/02/2025. The DSUs vest in 12 equal monthly installments from the grant date but will vest in full earlier if the holder remains in service until the next annual meeting or upon a change of control. Following the award, Errico beneficially owns 308,016 shares, composed of 217,051 directly owned shares, 1,296 shares held in a family trust, 11,000 held in another trust, and 52,054 shares that vested from prior DSUs. The DSUs carry no purchase price.
electroCore, Inc. director John P. Gandolfo was granted 19,011 Annual Deferred Stock Units on 09/02/2025 that vest in 12 equal monthly installments from the grant date, but accelerate to full vesting either one business day prior to the issuer's next annual stockholder meeting or immediately prior to a change of control, provided the reporting person remains in continuous service. After the grant, Mr. Gandolfo beneficially owns 88,098 shares, which includes 65,021 shares that had previously vested from earlier deferred unit grants.
electroCore, Inc. reported several corporate governance updates and voting results from its recent annual meeting. The Board appointed Elena Bonfiglioli, a senior healthcare and life sciences executive at Microsoft, as a new Class II director and expanded the Board from seven to eight members. She will receive the company’s standard non-employee director pay and an inaugural equity award.
The Board also named Thomas J. Errico, M.D. as chairman, succeeding F. Peter Cuneo, who retired and did not stand for re-election, with no disagreements cited regarding company matters. Director James C. Theofilos joined the Audit Committee.
Stockholders considered four proposals. An amendment to declassify the Board failed because it did not reach the required two-thirds of outstanding shares, despite 94.62% of votes cast supporting it. Three Class I directors were elected for terms expiring at the 2028 annual meeting, the appointment of CBIZ CPAs P.C. as independent auditor for 2025 was ratified, and named executive officer compensation was approved in a non-binding advisory vote.
Thomas J. Errico, a director of electroCore, Inc. (ECOR), purchased 15,000 common shares on 08/11/2025 at a weighted-average price of $4.47 per share. After the purchase he beneficially owns 281,401 shares, consisting of 217,051 shares owned directly, 1,296 and 11,000 shares held in two trusts, 50,672 vested Deferred Stock Units (DSUs), and 1,382 DSUs that vest monthly through September 3, 2025 (with full vesting earlier upon specified events). The filer notes a price range of $4.34 to $4.55 and will provide a breakdown of purchases on request.
Daniel S. Goldberger, Chief Executive Officer and director of electroCore, purchased 1,000 shares of common stock on 08/11/2025 at a weighted-average price of $4.23 per share (purchase prices ranged from $4.225 to $4.25). After the purchase he beneficially owns 291,565 shares. The filing notes that this total includes previously issued restricted stock units of 75,000 (25,000 vested; 50,000 vesting one-half on January 16, 2026 and January 16, 2027), 50,000 (33,333 vested; 16,667 vesting August 4, 2026), and 40,000 (vesting in one-third increments on January 18, 2026, January 18, 2027, and January 18, 2028).
electroCore, Inc. (ECOR) – Form 4 filing: On 08/01/2025 director James C. Theofilos was granted 22,156 restricted stock units (RSUs) under the company’s 2018 Omnibus Equity Compensation Plan. Each RSU converts into one common share and vests in 12 equal quarterly installments over 36 months. The award was recorded at $0 purchase price, indicating an incentive grant rather than an open-market buy. After the transaction, Theofilos’ direct beneficial ownership increased to 23,547 shares, consisting of 22,156 unvested RSUs and 1,391 previously held common shares. No shares were sold, no derivative securities were reported, and the form was signed on 08/05/2025.